Group 1: Innovation in Pharmaceuticals - The new policy introduced on June 10 aims to enhance the medical insurance drug list and establish a commercial insurance coverage directory for innovative drugs, indicating the formation of a dual support system of "basic medical insurance + commercial health insurance," which is expected to significantly increase the market penetration of innovative drugs in China [1] - Following this, on June 11, the Ministry of Industry and Information Technology and the National Development and Reform Commission jointly issued a document to promote the construction of biopharmaceutical pilot platforms, supporting the full-process capability building from research and development to industrialization [1] - The quality and efficiency of innovative drug research and development in China continue to improve, with over 20 Class 1 new drugs approved in the first five months of 2024, surpassing the same period in previous years, particularly in high-barrier areas such as oncology, autoimmune diseases, metabolic diseases, and rare diseases [1] - Chinese pharmaceutical companies are increasingly active on the international academic stage, with a record number of original research submissions from Chinese researchers at the 2025 ASCO annual meeting, including 11 items recognized as LBA (Latest Breakthrough Abstract) [1] - The recent high-value licensing agreements, such as the $6 billion deal between 3SBio and Pfizer, and the announcement by CSPC Pharmaceutical Group regarding three overseas collaborations totaling nearly $5 billion, indicate that Chinese innovative drugs have gained substantial endorsement from international pharmaceutical giants [1] Group 2: Biopharmaceuticals and Licensing - On June 11, during the Goldman Sachs Global Healthcare Conference, the management of China Biologic Products indicated that "licensing transactions will become a regular source of income and profit for the company," revealing that a "landmark transaction" is expected to be announced soon, generating strong market anticipation [2] - China Biologic Products' pipeline includes hot-target products such as HER2 bispecific ADC and EGFR/cMet ADC, with some varieties already in late-stage clinical trials, demonstrating strong competitiveness for international markets [2] - The upcoming American Diabetes Association (ADA) annual meeting on June 20 is expected to increase market attention on the GLP-1 field, which combines diabetes treatment and weight loss, representing another potential direction for domestic pharmaceutical companies to expand internationally [2] Group 3: Traditional Chinese Medicine (TCM) Protection Policies - Since June 2025, the National Medical Products Administration has approved three traditional Chinese medicines as secondary protected varieties and accepted an initial protection application, indicating a significant increase in regulatory focus on intellectual property protection for TCM [3] - The strengthening of the TCM protection system effectively provides "policy barriers + market exclusivity" for high-quality TCM companies, encouraging the development of original prescriptions and enhancing standardized production capabilities, reflecting the implementation of the "innovative drug model" in the TCM industry [3] - Regional pharmaceutical companies with unique product barriers, such as Runan Pharmaceutical and Anno Pharmaceutical, may open up national markets if they achieve branding and standardization [3] - Large TCM enterprises with research capabilities and brand influence, such as Tongrentang and Yunnan Baiyao, will continue to benefit from policy guidance and consumption upgrades [3] Group 4: NFT Market Trends - The NFT market, which exploded in 2021, has recently gained renewed attention from capital markets due to technological advancements, AI integration, and the expansion of Web3 applications, highlighting its dual attributes of "digital assets + consumer experience" [5] - The NFT concept sector saw a nearly 2% increase recently, with companies like Yifan Culture and Yuanlong Yatu reaching their price limits, reflecting market enthusiasm for the new round of competition around "virtual consumption + digital asset certification" [5] - This trend indicates that the value of NFTs is no longer limited to "collectibles," but is expanding into practical functions such as "rights certificates," "digital membership cards," and "on-chain asset certificates," enhancing their long-term sustainability [5]

凌子昂不仅是区块链领域的学术先锋，更是一位杰出的行业实践者。作为 NFTGo 的联合创始人，他推动了 NFT（非同质化代币）技术的发展与应用，为数 字资产的流通和价值实现提供了新的思路和解决方案。 在 5 月 25 日于杭州龙禧福朋喜来登酒店成功举办的亚洲品牌经济峰会 2025 杭州会议上，NFTGo 联合创始人凌子昂（笔名龙野）凭借其在区块链和数字货 币领域的杰出贡献，荣获第八届斯贝瑞奖 2025年度科技创新人物。这一殊荣不仅是对他过去九年在区块链行业深耕的肯定，更是对其未来潜力的高度期 待。 本次活动以 "创新无界，大浪淘沙始见金" 为主题，吸引了来自中国香港、迪拜、泰国、新加坡以及全国各地的 300 多位企业家、行业专家及品牌创始人。 活动旨在探讨品牌经济的创新趋势与数字化生态下的商业机遇，为企业领袖及创新实践者提供了一个高端对话与资源整合的平台。在众多优秀候选者中脱颖 而出，凌子昂的获奖充分彰显了他在区块链领域的卓越实力与行业影响力。 九年深耕，铸就行业标杆 凌子昂在区块链和数字货币行业拥有 9 年的研究和从业经验，是最早涉足比特币定价研究的学者之一。他著有多篇相关论文，并出版了《解锁新密码——从 区 ...